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A B S T R A C T
Budesonide (BUD), a poorly soluble anti-inflammatory drug, is used to treat patients suffering from asthma
and COPD (Chronic Obstructive Pulmonary Disease). Hydroxypropyl-β-cyclodextrin (HPβCD), a biocom-
patible cyclodextrin known to interact with cholesterol, is used as a drug-solubilizing agent in pharmaceutical
formulations. Budesonide administered as an inclusion complex within HPβCD (BUD:HPβCD) required a
quarter of the nominal dose of the suspension formulation and significantly reduced neutrophil induced in-
flammation in a COPD mouse model exceeding the effect of each molecule administered individually. This
suggests the role of lipid domains enriched in cholesterol for inflammatory signaling activation.
In this context, we investigated the effect of BUD:HPβCD on the biophysical properties of membrane
lipids. On cellular models (A549, lung epithelial cells), BUD:HPβCD extracted cholesterol similarly to
HPβCD. On large unilamellar vesicles (LUVs), by using the fluorescent probes diphenylhexatriene (DPH)
and calcein, we demonstrated an increase in membrane fluidity and permeability induced by BUD:HPβCD
in vesicles containing cholesterol. On giant unilamellar vesicles (GUVs) and lipid monolayers, BUD:HPβCD
induced the disruption of cholesterol-enriched raft-like liquid ordered domains as well as changes in lipid
packing and lipid desorption from the cholesterol monolayers, respectively. Except for membrane fluidity,
all these effects were enhanced when HPβCD was complexed with budesonide as compared with HPβCD.
Since cholesterol-enriched domains have been linked to membrane signaling including pathways involved in
inflammation processes, we hypothesized the effects of BUD:HPβCD could be partly mediated by changes in
the biophysical properties of cholesterol-enriched domains.
© 2017.
1. Introduction
The concept of biological membranes has evolved from simple
physical barriers providing individualization of the cell and subcellu-
lar compartments. This concept evolved to encompass cellular mem-
brane complexity [1–5] regarding its (i) composition, including hun-
dreds of lipid species, glycolipids and proteins; (ii) organization, in-
cluding asymmetry and lateral domains; and (iii) function, e.g. sig-
naling cascades, modulation of protein function and folding, cellular
communication, pathogen and drug interaction, among many others.
⁎ Corresponding author at: FACM/LDRI-UCL - Cellular and Molecular Pharmacology
Unit of the Louvain Drug Research Institute, Université catholique de Louvain,
Avenue E. Mounier 73, B1.73.05. B-1200 Bruxelles, Belgium.
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The presence of non-random domains within the lipid bilayer, e.g.
the so-called cholesterol and sphingolipid-enriched lipid rafts [6], fur-
ther supports the functional character of the membrane over a sim-
ple structural role. Cholesterol and sphingomyelin (SM)-enriched do-
mains show particular biophysical properties [7] creating an ordered
(liquid ordered, lo) lipid phase within the bulk membrane. Removal of
cholesterol by a randomly methylated-β-cyclodextrin (MeβCD) from
the lipid bilayer was shown to induce alterations in membrane bio-
physical properties [8]. Lipid rafts have been linked to several mem-
brane functions including signaling activation by immune receptors
such as TLR4 and CD44 [9] involved in inflammation and cancer [10].
Furthermore, changes in lipid membrane composition and/or biophys-
ical properties leading to significant membrane reorganization have
been linked to consequent disruption of cell signaling [11].
Cyclodextrins (CD) are cyclic oligosaccharides consisting of six
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α-1,4 glycosidic linkages [12]. The toroidal shape and hydrophobic
cavity of cyclodextrins allows the formation of inclusion complexes
with hydrophobic molecules of adequate size and shape through non
covalent interactions [13]. Hydroxypropyl-β-cyclodextrin (HPβCD) is
an FDA/EMA approved β-cyclodextrin derivative with increased wa-
ter solubility and low toxicity [14]. HPβCD is able to form complexes
with surfactants [15] and polymers [16] as well as with drug mole-
cules, such as curcumin [17] and budesonide [18].
Budesonide (BUD), a well-known anti-inflammatory drug is a glu-
cocorticoid commercially available as Pulmicort®. Budesonide is rec-
ommended for the treatment of asthma [19,20], acute onset of Chronic
Obstructive Pulmonary Disease (COPD) [21], allergic rhinitis [22]
and Crohn’s disease [23] among others, acting through the direct in-
hibition of expression of pro-inflammatory mediators [24]. Unfortu-
nately, with a logP of 3.2, budesonide is practically insoluble in water
at physiological pH, leading to low pulmonary deposition [25–27] and
reduced bioavailability, requiring the use of relatively high doses in
clinical use.
In patients with mild to moderate persistent asthma, budesonide
administered as an inclusion complex within HPβCD (BUD:HPβCD)
required a quarter of the nominal dose of the suspension formulation
due to a marked reduction in nebulization time [25,28]. Moreover,
co-administration of budesonide solubilized within HPβCD has been
shown to significantly reduce neutrophil induced inflammation in a
COPD mouse model exceeding the effect of each molecule adminis-
tered individually (Rocks et al., unpublished data).
In this context, a clear understanding of the molecular mechanism
of action of the BUD:HPβCD complex is essential to design tailored
and optimized therapeutic formulations.
This work focused on studying the effect of the BUD:HPβCD
complex on biophysical properties of lipid membrane. Since the
BUD:HPβCD complex is envisaged for aerial administration by nebu-
lization, lung epithelial cells (A549) are used for the study of its cellu-
lar toxicity and cholesterol extraction potential.
The effects of BUD:HPβCD on membrane biophysical proper-
ties were evaluated using membrane model systems. Large unilamel-
lar vesicles (LUVs) were used to study the interaction with mem-
brane cholesterol, via a fluorescent analogue of cholesterol (DHE),
and changes in membrane fluidity and permeability, by using the flu-
orescent probes diphenylhexatriene (DPH) and calcein, respectively.
Giant unilamellar vesicles (GUVs) were used to visualize the effect on
lateral phase separation and lipid organization using fluorescence mi-
croscopy. Finally, Langmuir studies characterized the effect on lipid
packing and desorption from the lipid monolayer.
2. Experimental procedures
2.1. Chemicals
The L-α-phosphatidylcholine (PC - Egg, Chicken), 1,2-dipalmi-
toyl-sn-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glyc-
ero-3-phosphocholine (DOPC), egg sphingomyelin (SM - Egg,
Chicken), N-palmitoyl-D-erythro-sphingosyl phosphoryl choline
(pSM - 16:0 SM d18:1/16:0), L-α-phosphatidylinositol (PI - Liver,
Bovine), cholesterol (Chol - ovine wool), er-
gosta-5,7,9(11),22-tetraen-3ß-ol (DHE - dehydroergosterol), 1,2-di-
oleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B
sulfonyl) (ammonium salt) (18:1 Liss Rho-PE) and 1,2-dipalmi-
toyl-sn-glycero-3-phospho ethanolamine-N-(biotinyl) (sodium salt)
(16:0 Biotinyl PE) were purchased from Avanti Polar Lipids (Al-
abaster, AL, USA). N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)-1,2-Di-
hexadecanoyl-sn-Glycero-3-Phospho ethanolamine, Triethy
lammonium Salt) (NBD-PE) was purchased from Life Technologies
(Leusden, Netherlands). 1,6-diphenyl-1,3,5-hexatriene (DPH), avidin
from egg white, 16,17-Butylidenebis(oxy)-11,21-dihydrox-
ypregna-1,4-diene-3,20-dione (Budesonide, BUD), Fluores-
cein-bis(methyliminodiacetic acid) (Calcein), and Sephadex® G-50
were purchased from Sigma-Aldrich (St. Louis, MO-USA). Methyl
β-cyclodextrin (MeβCD, Crysmeb®) and Hydroxypropyl-β-cyclodex-
trin (HPβCD, Kleptose® Oral Grade) were purchased from Roquette
(Lestrem, France).
Lipids and lipid probes were dissolved in chloroform, except DPH,
which was dissolved in tetrahydrofuran (THF), and were kept at
− 20 °C. The cyclodextrins were solubilized in PBS (NaCl 137 mM,
KCl 2.7 mM, Na2HPO4 9.6 mM and KH2PO4 1.15 mM, pH 7.4) at
their maximal concentration of 30 mM for MeβCD and 250 mM for
HPβCD. Budesonide was firstly dissolved in DMSO at 100 mM and
then diluted to 0.1 mM in a PBS solution (DMSO 0.1% v/v). All or-
ganic solvents used were Spectronorm grade from VWR (Radnor, PA,
USA) or Emsure grade from Merck (Darmstadt, Germany).
2.2. Preparation of the Budesonide-Cyclodextrin complex
The Budesonide-Cyclodextrin complex (BUD:HPβCD) was pre-
pared by adding budesonide to a HPβCD solution in PBS during 48 h
under magnetic agitation or 2 h using a T-25 Ultra-Turrax® labora-
tory mixer from IKA (Staufen, Germany). The amount of budesonide
effectively encapsulated was determined using HPLC-MS quantifica-
tion as described by Dufour et al. [26].
2.3. A549 cell culturing, cytotoxicity assay and cholesterol dosage
A549 cells were cultured in DMEM medium – from
Thermo-Fisher Scientific (Waltham, MA-USA) – supplemented with
10% of Fetal Bovine Serum (FBS) at 37 °C and under 5% CO2.
A549 cells, grown to 80% confluence in 96-well plates, were ex-
posed to MeβCD, HPβCD, BUD:HPβCD complex and budesonide in
low-serum conditions (1% FBS). Cell death was inferred from cell
membrane permeabilization to cytoplasmic Lactate Dehydrogenase
(LDH). LDH activity was measured in triplicate using the Cytotoxic-
ity Detection Kitplus (LDH) version 06 from Sigma-Aldrich (St. Louis,
MO-USA).
The amount of protein was determined using the DCTM Protein As-
say Kit from Bio-Rad (Hercules, CA-USA).
After extraction, total cholesterol [29] was quantified using the
Amplex® Red Cholesterol Assay Kit from Thermo-Fisher Scientific
(Waltham, MA-USA).
2.4. Preparation of large unilamellar vesicles (LUVs)
Large unilamellar vesicles (LUVs) were prepared by extrusion
from multilamellar vesicles (MLVs). Lipids were mixed at the mo-
lar ratios of PC:SM:PI (4:4:3) and PC:SM:PI:Chol (4:4:3:5.5) with
a probe-to-lipid ratio of 1:100 for DHE and 1:300 for DPH and a
final lipid concentration of 10 mM. A lipid film was obtained after
solvent evaporation over 2 h, using a R-210 rotavapor from Buchi
(Flawil, Switzerland) coupled to a vacuum pump HZ 2C from Vacu-
ubrand (Wertheim, Germany), followed by minimum 2 h in an exsic-
cator under vacuum. The lipid film was hydrated in Tris-HCl buffer
(Tris-HCl 10 mM, NaCl 135 mM, pH 7.4). MLVs were obtained by
repeated cycles (× 7) of vortex/freeze/thawing. LUVs were obtained
by MLV extrusion (× 21) using a mini-extruder system from Avanti
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bonate Nuclepore Track Etch membrane filter from Whatman® (GE
Healthcare, Little Chalfont, UK). Total lipids were quantified using
the method from Rouser [30] and diluted to the desired final concen-
tration in PBS.
2.5. Vesicle size and ζ-potential determinations
LUV mean size and ζ-potential were determined using a Zetasizer
Nano SZ equipment from Malvern Instruments (Grovewood Road,
UK) with patented NIBS (non-invasive back scatter) technology and
the recommended software. Particle size distribution and the poly-
dispersion index (PdI) measurements were performed by Dynamic
Light Scattering (DLS) technology using 12 mm square polystyrene
cuvettes in a thermostated chamber at 25 °C. Particle charge (ζ-poten-
tial) was measured using Dynamic Electrophoretic Mobility (DEM)
using a disposable folded capillary cell in a thermostated chamber at
25 °C.
2.6. Fluorescence spectroscopy measurements
All fluorescence measurements were carried out with a LS55 spec-
trofluorimeter from Perkin Elmer (Waltham, MA-USA) in right angle
geometry. Temperature was stabilized at 25 °C using a C25P Phoenix
II thermostating water bath from Thermo Scientific (Waltham,
MA-USA).
2.7. Dehydroergosterol (DHE) Spectroscopy
The ability of BUD:HPβCD and HPβCD to bind to cholesterol was
investigated using DHE fluorescence spectroscopy.
DHE (10 μM) was prepared in PBS pH 7.4 containing 0.1%
DMSO [31]. Fluorescence emission spectra of DHE in buffer solu-
tion were recorded at increasing concentrations of BUD:HPβCD or
HPβCD, and the intensity of the monomeric versus microcrystalline
peak ratio was plotted against log10 concentration. The excitation
monochromator was set at 328 nm, and the emission spectra were
recorded from 340 to 545 nm [32,33]. The influence of DMSO and
DHE concentration was controlled.
To probe the interaction between BUD:HPβCD or HPβCD with
cholesterol in a lipid environment, 1 mol% of DHE was incorporated
in LUVs composed of PC:SM:PI:Chol (4:4:3:5.5). Maximal emission
of DHE was observed around 372, 404 and 424 nm, as described pre-
viously in membrane systems [34]. LUVs (5 μM) were incubated with
increasing BUD:HPβCD or HPβCD concentrations for 3 h at 25 °C.
2.8. Diphenylhexatriene fluorescence polarization
Molecule polarization was quantified using steady state fluores-
cence anisotropy, < r >, measurements calculated using Eq. (1):
where the different intensities IIJ are the steady state polarized verti-
cal and horizontal components of fluorescence emission with excita-
tion vertical (IVV and IVH) and horizontal (IHV and IHH) to the emission
axis. The latter pair of components was used to calculate the G factor
(G = IHV / IHH).
DPH concentration was determined by UV spectroscopy and ad-
justed to 100 μM in tetrahydrofuran. Final lipid concentration was
adjusted to 50 μM in PBS pH 7.4. LUVs were incubated with
BUD:HPβCD or HPβCD for 60 min at 25 °C shielded from light.
2.9. Calcein release
Changes in the membrane permeability were followed by deter-
mining the leakage of entrapped calcein at self-quenching concen-
trations, from liposomes [35]. Briefly, the dried lipid films were hy-
drated with a solution of purified calcein (73 mM) in Tris-HCl buffer
at pH 7.4 and osmolarity of 404 mOsm/kg. The un-encapsulated dye
was removed by the mini-column centrifugation technique using
Sephadex® G-50 [36]. The liposomes were diluted to a final lipid con-
centration of 5 μM in an isosmotic Tris-HCl (Tris 10 mM and NaCl
188 mM) pH 7.4 buffer and stabilized for 10 min at 25 °C. Values
were recorded for 30 s before addition of BUD:HPβCD or HPβCD
at increasing final concentrations of 10 and 20 mM. After the addi-
tion of the compounds, the fluorescence intensities were continuously
recorded as a function of time for up to 500 s. The percentage of cal-
cein released was determined according to Eq. (2):
where Ft is the fluorescence signal measured at a time t in the presence
of compounds, Fcontr is the fluorescence signal measured at the same
time t for control liposomes, and Ftot is the total fluorescence signal
obtained after complete disruption of the liposomes by 0.02% Triton
X-100.
2.10. Preparation of giant unilamellar vesicles (GUVs)
Giant unilamellar vesicles (GUVs) were prepared using the elec-
troformation method [37–39]. In brief, mixtures of DOPC:pSM (1:1)
and DOPC:pSM:Chol (1:1:3) with biotinylated lipid-to-lipid ratio of
1:106 Biotinyl-PE and probe-to-lipid ratio of 1:750 for Rho-DOPE
and 1:250 for NBD-PE were prepared. A small volume (4 μl) of lipid
mixture (4 mM) was evenly spread on the surface of an ITO coated
glass lamella and the solvent was allowed to evaporate over 5 min. A
1 mm thick silicon gasket was used to form a sealed reaction cham-
ber. Sucrose-Tris (475 μL) was added and a second ITO covered glass
lamella was overlaid. The GUVs were formed at 60 °C over a 2 h ex-
posure to a sinusoidal signal with a peak-to-peak intensity of 1 V and
frequency of 500 Hz. The GUVs were used within the day.
2.11. Fluorescence microscopy measurements
GUVs were used to visualize the lipid lateral segregation and
phase separation. GUVs were placed in a μ-Slide 8-well chamber
from Ibidi (Martinsried, Germany) previously coated with avidin 0.1%
for a minimum of 2 h. GUVs were observed using an Axio Ob-
server Z1 inverted microscope (Carl Zeiss, Jena, Germany) equipped
with a model CSU-X1 spinning disk (Yokogawa Electric Corporation,
Tokyo, Japan) and a Plan-Apochromat 100 ×/1.40 Oil DIC M27 ob-
jective (Carl Zeiss, Jena, Germany). Images were recorded and ana-
lyzed with an AxioCamMR3 camera using Carl Zeiss AxioVision®
4.8.2 software. The red channel was used for Rho-DOPE (excitation/
emission at 561/617 nm) and in the green channel for NBD-PE (exci-
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2.12. Surface pressure–area (π-A) compression isotherms
To examine the effect of BUD:HPβCD and HPβCD, on lipid pack-
ing, surface pressure–area (π-A), compression isotherms were
recorded with an automated Langmuir trough (KSV Mini-trough KSV
Instruments Ltd., Helsinki, Finland-width = 7.5 cm, length = 37 cm),
two hydrophilic Delrin mobile barriers (symmetric compression), a
platinum Wilhelmy plate, and a temperature probe. The system was
enclosed in a Plexiglas® box, and the temperature was maintained at
22.0 ± 1.0 °C.
The cleanliness of the surface was ensured by aspiration of the
sub-phase surface before each experiment. Once the temperature was
stabilized, the barriers were fully closed and reopened and, if a varia-
tion in surface pressure of less than 0.5 mM/m was observed, the lipid
was deposed on the air-liquid interface surface with a micro-syringe
(Hamilton, USA). The platinum plate was cleaned by rinsing with iso-
propanol and heating to red glow in-between experiments. PBS pH 7.4
was used as the subphase. Lipids (Chol, SM, POPC, or the nega-
tively-charged lipid, PI) were dissolved at a concentration of 2 mM in
CHCl3:MeOH (2:1 v/v) and were spread at the liquid/air interface with
a micro-syringe (Hamilton, USA). The volume was chosen in order
to obtain an optimal isotherm compression curve (starting at 0 mN/m
and showing a collapse at the end of the compression).
After an equilibration time of 15 min, the film was compressed
at a rate of 10 mm/min. BUD:HPβCD (0.04:1 mM:mM) or HPβCD
(1 mM) were solubilized in the subphase before spreading the lipid us-
ing the same amount of lipid as for the control assays. The same pro-
cedure as the one used for experiments without cyclodextrin was ap-
plied. Each compression isotherm was repeated at least two times; the
relative standard deviation in surface pressure and area was ≤ 5%.
2.13. Surface pressure–time (π-t) adsorption isotherms
BUD:HPβCD or HPβCD effect on lipid molecular area were as-
sessed by measuring lipid molecular area over time upon incubation
with the compounds (π-t isotherms). To this end, the same set-up as
described for the surface pressure–area (π-A) compression isotherms
was used with a different automated Langmuir trough (KSV
Mini-trough KSV Instruments Ltd., Helsinki, Finland-width = 7.5 cm,
length = 20 cm).
The lipids (Chol, SM, POPC, or PI) were added until a surface
pressure of 30 mN/m was achieved and, after a stabilization period of
15 min, surface pressure over time was recorded. After the acquisi-
tion of a 200 s baseline to verify the stability of the monolayer, the
compounds were injected into the subphase using specialized injection
supports to a final concentration of 0.04:1 mM:mM of BUD:HPβCD
or 1 mM of HPβCD. Surface pressure was recorded until a plateau was
observed.
The obtained curves were analyzed by a fitting on a 2-phase expo-
nential regression from where the estimated plateau values were ex-
tracted.
2.14. Statistical analysis
All data manipulation, graphical presentation and statistical analy-
sis was performed using Microsoft® Excel® (2016, Microsoft®, Red-
mond – Washington USA) and GraphPad Prism® (version 4.03 for
Windows, GraphPad Software Inc., La Jolla - California USA, www.
graphpad.com).
3. Results
3.1. Cell toxicity and cell cholesterol depletion
We first evaluated the cytotoxicity of the complex BUD:HPβCD
in comparison with the highly hydrophobic anti-inflammatory drug,
budesonide (BUD) and HPβCD.
The cytotoxic effect was determined by following LDH release on
lung epithelial cells (A549). For concentrations in cyclodextrin vary-
ing from 0 to 10 mM and after 4 h of incubation (Fig. 1.a), the cy-
totoxicity induced by BUD:HPβCD or HPβCD was lower (ca. 10%)
as compared with budesonide. At 25 mM in cyclodextrin and
Fig. 1. Cell toxicity and effect on cholesterol of BUD:HPβCD, HPβCD, and BUD on
lung epithelial cells. Percentage of LDH released from A549 lung epithelial cells (a)
at 4 h for BUD:HPβCD (squares) 0.04:1 to 2.03:50 mM:mM, HPβCD (circles) 1 to
50 mM in cyclodextrin, or BUD (triangles) 0.04 to 2.03 mM and (b) for BUD:HPβCD
0.41:10 mM:mM (squares), HPβCD 10 mM (circles), or BUD 0.41 mM (triangles) at 1,
2, 4 and 24 h. (c) Total cellular cholesterol (normalized to total amount of proteins) for
A549 lung epithelial cells treated with BUD:HPβCD 0.41:10 mM:mM, HPβCD 10 mM,
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over, significant toxicity (ca. 40%) was observed. Regardless the con-
centrations in cyclodextrin (from 0 to 25 mM), the cytotoxicity in-
duced by the complex (BUD:HPβCD) was lower as compared to that
observed with budesonide alone. At 50 mM in cyclodextrin, cyto-
toxicity was comparable for HPβCD, BUD:HPβCD and budesonide.
Regarding the time dependency cytotoxic effect induced by
BUD:HPβCD (0.41:10 mM:mM), budesonide (0.41 mM), and
HPβCD (10 mM) (Fig. 1.b), we didn't have any effect for 2 h of in-
cubation. After 4 h, LDH release started and after 24 h of incubation,
BUD:HPβCD and budesonide, showed more than 35% of LDH re-
lease. In comparison, HPβCD induced less than 10% LDH release.
Selecting non-toxic conditions, we quantified the extraction of
cholesterol from cells (Fig. 1.c). MeβCD (5 mM) was used as a pos-
itive control. For BUD:HPβCD (0.41:10 mM:mM) and HPβCD
(10 mM), after 45 min of incubation, the amount of total cholesterol
(normalized to total protein) was reduced by ca. 45%. HPβCD was
able to significantly extract cholesterol from the membrane regardless
of previous complexation with budesonide.
3.2. Interaction with membrane model systems
The effect of the extraction of cholesterol induced by
BUD:HPβCD and HPβCD on membrane biophysical properties was
further characterized in membrane model systems.
To determine the concentration range of HPβCD without vesicle
destabilization, vesicle mean size and ζ-potential were measured upon
incubation with increasing concentration of HPβCD (up to 100 mM,
Fig. S1). Briefly, at ratios of HPβCD:lipid exceeding 5000:1 (HPβCD
25 mM to lipids 5 μM), the fraction of vesicles within the diameter
range of the control samples became significantly reduced. Therefore,
a 25 mM threshold of HPβCD was set to avoid experimental artefacts
and/or skewed results.
3.3. Interaction with sterols in aqueous solution
The interaction of BUD:HPβCD and HPβCD with cholesterol was
studied using a cholesterol analogue presenting similar behavior in
aqueous solution and biological membranes [33,34,40], the dehy-
droergosterol (DHE). Especially, it shows similar properties regard-
ing lateral phase separation compared to cholesterol [41]. Lateral in-
teractions between sterols are responsible for an increase in DHE fluo-
rescence quantum yield at higher wavelengths of emission [32,42,43].
DHE is a self-quenching molecule and fluorescence emission of the
monomeric peak (I372) occurs upon the dissolution of cholesterol-en-
riched domains [44] or desorption of DHE from the lipid bilayer [45]
by βCDs. DHE aggregates in solution can be quantified using the fluo-
rescence emission ratio I372/I424 [34], corresponding to the monomeric
species over the aggregate forms, such as DHE microcrystals in so-
lution [34,42]. The spectral properties of DHE, namely fluorescence
intensity and peak ratios (I372/I424), are used to infer upon the microen-
vironment of cholesterol, in agreement with results showing compara-
ble, although slightly faster, extraction of DHE in mixed monolayers
(sterols:POPC 30:70) by HPβCD, to that of cholesterol [45].
The interaction of increasing concentrations of BUD:HPβCD and
HPβCD with DHE in solution was characterized (Fig. 2) and com-
parative control studies were performed using MeβCD (Fig. S2, a, b).
An increase of the intensity of the monomeric peak at 372 nm (Fig.
2.a), concomitant with an increase in the ratio of the monomeric
over the aggregate form of DHE (Fig. 2.b) was observed. The effect
started at 1 mM HPβCD and a plateau value was reached at 10 mM.
Regarding the ratio of the monomeric over the aggregate form of
Fig. 2. Fluorescence of DHE in aqueous solution upon interaction with BUD-HPβCD,
and HPβCD. (a) Fluorescence emission intensity at 372 nm and (b) ratio of peak inten-
sity between 372 and 424 nm upon addition of BUD:HPβCD (squares; dotted line), or
HPβCD (circles; solid line). The lines correspond to a non-linear fitting of a non-loga-
rithmic sigmoidal Hill growth function to the data.
DHE (I372/I424), the effect was observed at slightly lower concentra-
tions of HPβCD when complexed with the budesonide. No effect was
observed for budesonide alone (not shown). Overall, the increase in
fluorescence of the DHE monomeric peak indicates the solubilisation
of DHE by the HPβCDs in a concentration dependent manner, which
is likely due to the formation of HPβCD-sterol complexes as previ-
ously described [45].
3.4. Interaction with sterols in a lipid membrane
In order to study the effect of increasing concentrations of cy-
clodextrin (HPβCD and BUD:HPβCD) on the microenvironment of
cholesterol within lipid bilayers, a small fraction of DHE was incor-
porated into LUVs mimicking the lipid composition of plasma mem-
brane (PC:SM:PI:Chol 4:4:3:5.5) (Fig. 3) and comparative control
studies were performed using MeβCD (Fig. S2, c, d).
Fig. 3 presents the fluorescence intensity at the 372 nm emis-
sion peak of DHE monomeric form (Fig. 3.a) and the ratio of emis-
sion at 372 nm over 424 nm (Fig. 3.b) upon interaction with the
BUD-HPβCD complex and HPβCD. An increase in fluorescence in-
tensity of DHE (Fig. 3.a) was observed, which was less pronounced
as compared with DHE microcrystals in solution. This can be due
to the lower amount of DHE within the membranes (200 × less con-
centrated). Moreover, DHE microenvironment can affect βCD poten-
tial for complexing with cholesterol [45], the dissolution of an aggre-
gate form in solution being likely facilitated over the extraction of
DHE stabilized within a lipid membrane. The results showed that, re-
gardless of complexation with budesonide, HPβCD was able to in-
crease the fluorescence of DHE monomeric peak. Regarding the ratio
of the monomeric over the aggregate form of DHE within the bilayer
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Fig. 3. Fluorescence of DHE within LUVs upon interaction with BUD:HPβCD, and
HPβCD. (a) Emission at the monomeric 372 nm peak and (b) ratio of emission at
372 nm over 424 nm upon interaction with BUD-HPβCD (squares; dotted line), or
HPβCD (circles; solid line), with LUVs composed of PC:SM:PI:Chol 4:4:3:5.5. DHE
was present at 1 mol% of total lipid concentration. Measurements were performed at
25 °C in triplicate. The lines correspond to a non-linear fitting of a non-logarithmic sig-
moidal Hill growth function to the data.
by the HPβCD (Fig. 2.b). No major difference was observed when the
effect of BUD-HPβCD was compared to that of HPβCD.
DHE de-quenching can be due to either the disruption of choles-
terol-enriched domains [34] or to extraction from membrane by the
HPβCD [45]. Measurements of emission intensity over time (data not
shown) showing an instantaneous endpoint de-quenching of DHE,
suggest DHE extraction from the membrane instead of the rearrange-
ment of lipid lateral organization, which would occur over several
minutes. Overall, increase in DHE monomeric peak emission by
BUD:HPβCD or HPβCD demonstrated changes of the sterol environ-
ment in agreement with DHE extraction from the membrane [44]. Be-
cause cholesterol is a main modulator of membrane fluidity, its ex-
traction from membrane by BUD:HPβCD and HPβCD could modify
membrane fluidity.
3.5. Effect on membrane fluidity
Cholesterol increases the fluidity of very ordered domains and in-
creases the rigidity of very disordered domains. Moreover, cholesterol
and sphingolipid-enriched domains, i.e. raft-like domains, present de-
creased fluidity and hydration when compared to the bulk membrane.
The lipid dynamics of acyl lipid chains can be monitored using
diphenylhexatriene (DPH), a dye that probes the hydrophobic core of
the membrane [46]. The degree of polarization of DPH, measured by
its fluorescence anisotropy (< r >), increases as membrane fluidity de-
creases. Fig. 4 shows the variation of DPH anisotropy in LUVs lack-
ing cholesterol (PC:SM:PI 4:4:3) and LUVs containing cholesterol
(PC:SM:PI:Chol 4:4:3:5.5) upon interaction with the BUD:HPβCD
complex or HPβCD.
Fig. 4. Membrane fluidity measurements of LUVs containing and lacking cholesterol
upon interaction with BUD:HPβCD, and HPβCD. Measurement of DPH anisotropy
(< r >) upon addition of BUD:HPβCD complex (grey bars), or HPβCD (black bars) to
LUVs composed of (a) PC:SM:PI (4:4:3) or (b) PC:SM:PI:Chol (4:4:3:5.5) containing
DPH (1:300 molar ratio).
For vesicles lacking cholesterol, the results (Fig. 4.a) show a fluid
membrane (ld) in the absence of cholesterol (< r > of ca. 0.15), as is
expected for a lipid mixture containing phospholipid:sphingolipid at a
molar ratio of 7:4 at 25 °C [47]. Adding cholesterol (Fig. 4.b) reduced
membrane fluidity (< r > of ca. 0.25), indicating the presence of a liq-
uid ordered (lo) phase typical of a mixture containing ca. 33 mol% of
cholesterol and 25 mol% of SM at 25 °C [47].
Upon incubation of cholesterol-free vesicles with HPβCD (Fig.
4.a), an increase in DPH anisotropy to values suggesting a gel phase
(< r > of ca. 0.30) was observed at the lower concentration of HPβCD
(10 mM). Increasing HPβCD concentration caused a concentration de-
pendent increase in membrane fluidity back to control values. These
results are in agreement with literature [48,49,50]. Since we excluded
increase in average size of liposomes (Fig. S1) as suggested in litera-
ture [48,49], the formation of supra-molecular cyclodextrin structures
on the surface of the lipid bilayer is likely the mechanism involved in
decrease in membrane fluidity [50].
The incubation of BUD:HPβCD complex or HPβCD with cho-
lesterol-enriched membranes (Fig. 4.b) resulted in a dose-dependent
decrease of anisotropy indicating an increase in membrane fluidity.
This effect reached a plateau at a value of anisotropy indicative of a
very fluid cholesterol-free membrane (< r > of ca. 0.10) at 30 mM of
CD. Moreover, the cholesterol depleted membrane by HPβCD became
more fluid (< r > of ca. 0.10) than the control mixture without choles-
terol (< r > of ca. 0.15). As for the cholesterol-free LUVs, the extrac-
tion of other membrane rigidifying lipids, such as the high Tm sphin-
golipid, sphingomyelin also located within the lipid raft, is likely. De-
spite a larger affinity of βCD towards cholesterol, other lipids may
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As was observed for DHE extraction from the membrane, HPβCD
complexation with budesonide did not show any effect on the induced
changes to membrane fluidity as compared with HPβCD. The pres-
ence of free budesonide did not change the membrane fluidity.
In conclusion, BUD:HPβCD or HPβCD incubation with choles-
terol-enriched membranes lead to increased membrane fluidity. This is
in agreement with the extraction of cholesterol and destabilization of
the liquid ordered cholesterol- and sphingolipid-enriched raft-like do-
mains. Altogether, this suggests a lateral reorganization of the lipids,
which could be associated with increased membrane permeability.
3.6. Effect on membrane permeability
Permeation of the plasma membrane is often the first barrier for
drug entry into the cell, as is the case for budesonide. Therefore, in-
creased membrane permeability may be one of the possible modu-
lators of drug bioavailability and efficacy. The permeabilization of
the membrane can be determined by quantifying the increase in flu-
orescence emission of the self-quenching calcein upon release from
permeabilized membranes. Calcein fluorescence intensity was mea-
sured upon interaction of BUD-HPβCD (0.41:10 mM:mM and
0.82:20 mM:mM) or HPβCD (10 and 20 mM) with vesicles lack-
ing cholesterol (PC:SM:PI 4:4:3) and vesicles containing cholesterol
(PC:SM:PI:Chol 4:4:3:5.5) (Fig. 5 and Fig. S3).
In the absence of cholesterol, BUD:HPβCD (20 mM in cyclodex-
trins) did not induce calcein leakage. In the presence of cholesterol,
the extent of permeabilization increased to reach a plateau value
(around 30% of calcein release) after 200 s (Fig. 5.top). The effect was
dependent upon the concentration of cyclodextrins (10 mM < 20 mM
in cyclodextrins) (Fig. 5.middle). These results were consistent with
the increase in lipid extraction and consequent leakage of encapsulated
calcein.
As compared to HPβCD alone, incubation with the BUD:HPβCD
increased the rate of calcein release (Fig. 5.bottom) without affecting
the percentage of calcein released at equilibrium. The increase in rate
of membrane permeabilization may be explained by either (i) perme-
ation of budesonide through the membrane or (ii) increase in HPβCD
affinity towards the membrane induced by budesonide.
3.7. Effect on membrane phase separation
The interaction of BUD:HPβCD and HPβCD with cholesterol may
lead to the disruption of the lipid raft domains, typically composed of
cholesterol and sphingolipids.
Confocal fluorescence microscopy was used to observe the
changes in lipid phase separation over time upon interaction with
BUD:HPβCD or HPβCD. Control GUVs and lipid-raft model GUVs,
composed of DOPC:pSM (1:1) and DOPC:pSM:Chol (1:1:3) [50],
were labeled with Rho-DOPE (red channel) and NBD-PE (green chan-
nel) for the liquid disordered (ld) and liquid ordered (lo) domains, re-
spectively.
Typically, the GUV population was relatively heterogeneous re-
garding vesicle size with diameters centered on ca. 15 μm (± 5 μm).
Overall, no effect was observed by incubation with budesonide.
While the majority of the GUVs immediately presented changes in
lipid phase separation upon interaction with the HPβCD, a subpopula-
tion, mostly comprised of the very small GUVS (under 10 μm in diam-
eter) began to exhibit observable changes only after more than 30 min
of incubation or remained apparently unaffected.
In the absence of cholesterol (Fig. 6-left), the DOPC:pSM 1:1
membranes show a ld/so (red/dark) phase separation as expected [47].
Fig. 5. Calcein leakage from LUVs containing and lacking cholesterol upon interac-
tion with BUD:HPβCD, and HPβCD. Comparison of leakage of calcein (top) from
PC:SM:PI (black line) and PC:SM:PI:Chol (gray line) vesicles in the presence of
BUD:HPβCD 0.82:20 mM:mM; (middle) from PC:SM:PI:Chol vesicles in the presence
of BUD:HPβCD 0.41:10 mM:mM (black line) and BUD:HPβCD 0.82:20 mM:mM
(gray line); and (bottom) from PC:SM:PI:Chol vesicles upon interaction with
BUD:HPβCD 0.82:20 mM:mM (gray line) and 20 mM of HPβCD 20 mM (black line).
The curves are representative of three independent experiments.
Interaction with either BUD:HPβCD or HPβCD removed any micro-
scopic phase separation and a single ld phase (red) was observed.
As was observed for the kinetics of membrane permeabilization (Fig.
5.c), the effect occurred at earlier incubation times for the
BUD:HPβCD (under 5 min) when compared with the HPβCD alone
(ca. 15 min).
In the presence of cholesterol (Fig. 6-right), no microscopic ld/lo
phase separation was visible as expected for a mixture containing
60 mol% of cholesterol. Interaction with the HPβCD, and
BUD:HPβCD alike, caused the appearance of observable lo domains
after 5 min of incubation, congruent with a decrease in the molar frac-
tion of cholesterol. Longer incubation times showed further decrease
of the lo phase giving yield to ld domains (eventually a single ld phase
was visible). Within 45 min, a ld/so phase separation was observed, in-
dicating a negligible amount or the absence of cholesterol within the
membrane.
The decrease and, ultimately, the disappearance, of the liquid or-
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Fig. 6. Confocal fluorescence microscopy imaging of membrane phase separation in GUVs upon incubation with BUD:HPβCD, and HPβCD. Imaging of membrane domains in
GUVs composed of (left) DOPC:pSM (1:1) and (right) DOPC:pSM:Chol (1:1:3) before (top, control) and after (descending) 5, 15 and 45 min with the BUD:HPβCD complex or
HPβCD. DOPC:pSM vesicles were labeled with Rho-DOPE (red channel) to visualize the liquid disordered (ld)/solid ordered (so) phase separation in red/dark. DOPC:pSM:Chol were
labeled with Rho-DOPE (red channel) and NBD-PE (green channel) to visualize the liquid disordered (ld)/liquid ordered (lo) phase separation in red/green channels, respectively. The
absence of fluorescent labelling indicates a solid ordered phase (so) and the co-localization of both probes (yellow) indicates a lack of observable phase separation.
is consistent with removal of cholesterol from the membrane by inter-
action with HPβCD [51].
3.8. Effect on lipid mean molecular area
To further characterize the effect of BUD:HPβCD and HPβCD on
the biophysical membrane properties, we compared the isotherms of
lipid monolayers spread with BUD:HPβCD or HPβCD aqueous solu-
tions to those deposited on PBS buffer (Fig. 7).
In presence of BUD:HPβCD or HPβCD, a long plateau at a
non-zero surface pressure was observed at large molecular areas what-
ever the composition of the monolayer. It suggests that BUD:HPβCD
or HPβCD are able to adsorb to the lipid monolayer in a gaseous state
[52,53] despite the fact that they do not change the surface pressure by
themselves in the absence of lipids.
For all the lipids, further compression of monolayers in presence
of BUD:HPβCD and HPβCD induced a progressive increase of the
surface pressure indicating the formation of a liquid-expanded mono
layer. Finally, at low molecular areas, the isotherms showed either a
final plateau at constant surface pressure or a sharp decrease in surface
pressure corresponding to the collapse of the monolayer. In the case
of cholesterol (Fig. 7.a) and SM (Fig. 7.b) monolayers and in a lesser
extent for PI (Fig. 7.d) monolayers, the profile of the lipid isotherm
in the presence of BUD:HPβCD or HPβCD is different from that ex-
pected if the lipid molecules were simply removed from the interface.
The lipid/ BUD:HPβCD or HPβCD interactions leads to the formation
of new system at the interface.
The molecular area and surface pressure at which the membrane
collapsed (referred to as AC and SPC, respectively) were used to quan-
titatively compare the interfacial behavior of lipids in presence or in
absence of BUD:HPβCD or HPβCD (Fig. 7.e and f).
In the case of cholesterol monolayers (Fig. 7.a and e), a decrease
in AC (Fig. 7.a and e) was observed with BUD:HPβCD to a higher
extent as compared with HPβCD. A reduction of the lipid molecular
area in presence of exogenous drug can arise from desorption of the
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Fig. 7. Effect of BUD:HPβCD, and HPβCD on Chol, eSM, POPC and PI monolayers. Surface pressure-area (Π-A) compression isotherms of the pure lipids (a) Chol, (b) eSM, (c)
POPC and (d) PI with a subphase composed of PBS (triangles), BUD:HPβCD 0.2:5 mM:mM (squares), or HPβCD 5 mM (circles). (inset) Surface pressure-time (Π-t) curves for the
lipids with a subphase composed of PBS with BUD:HPβCD 0.04:1 mM (squares), or HPβCD 1 mM (circles) fitted with a non-linear regression curve. (e) Molecular area at the sur-
face pressure onset (A0) and (f) two-dimensional compressibility factor (Cs) for the higher compression for the pure lipid (light grey) and in the presence of BUD:HPβCD (dark grey)
or HPβCD (grey) calculated from the surface pressure-area (Π-A) isotherms as described by [61]. The curves were recorded at 22 °C (± 1 °C) and are representative of replicated
assays.
the interfacial monolayer (domain packing, nucleation) [53]. The sig-
nificant decrease in SPC (Fig. 7.f) in presence of HPβCD and even
much more in presence of BUD:HPβCD means that the interaction
of HPβCD destabilizes the liquid-condensed phase of the cholesterol
monolayer, which is in accordance with the fluidification effect shown
by DPH fluorescence polarization.
The injection of BUD:HPβCD or HPβCD beneath the cholesterol
monolayer initially spread at the air-water interface until a surface
pressure of 30 mN/m and maintained at a constant spreading surface
gave rise to a rapid and important decrease of the surface pressure
(Fig. 7.a-inset). These results are in favor of cholesterol depletion from
the interface, as also shown for βCD in previous studies [45,52,53].
HPβCD and BUD:HPβCD also reduces the AC of SM monolayers
(Fig. 7.b and e) without significantly affecting SPC (Fig. 7.f) suggest-
ing some lipid desorption from the interface without changing lipid
packing. The extraction of SM from the interface by HPβCD was
in agreement with the decrease of surface pressure in the time-de-
pendence surface pressure experiments. In contrast, BUD:HPβCD in-
creased the surface pressure when it is injected under the SM mono-
layer. This suggests that two parallel phenomena occurs when
BUD:HPβCD interacts with the SM monolayer, (i) a limited
depletion of SM from the monolayer and (ii) an adsorption of
BUD:HPβCD molecules to the interface.
In the case of POPC monolayers (Fig. 7.c, d, e), the presence of
HPβCD decreased AC (Fig. 7e) but in a lesser extent than in the case of
cholesterol and SM (reduction of ~ 17% for POPC vs ~ 30% for cho-
lesterol and SM). No effect on AC was observed for the BUD:HPβCD
complex with POPC or for either compound with PI monolayer. As
for SM monolayer, HPβCD or BUD:HPβCD did not greatly affect the
interfacial stability of POPC or PI monolayers (Fig. 7.f). However,
while the HPβCD caused lipid desorption from the monolayer (Fig.
7.b–d-insets), the BUD:HPβCD complex increased slightly the sur-
face pressure when injected under the POPC or PI monolayers. Inser-
tion of budesonide and/or BUD:HPβCD into the monolayer can also
occurs in these cases.
Overall, the BUD:HPBCD complex shows i) increased extent of
destabilization of cholesterol monolayers and ii) adsorption into the
phospholipid monolayers when compared to the free HPBCD. This
might be due to i) a possible increase in affinity/efficacy of the
HPβCD regarding cholesterol-containing membranes due to the pres-
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4. Discussion
Membrane cholesterol has several important properties including
the lateral segregation into cholesterol and sphingolipid-enriched do-
mains known as lipid rafts [6]. These ordered domains have been
shown to be essential for creating an appropriate microenvironment
for signal reception and transduction. Lipid rafts are able to stabilize
and cluster the receptor structures. This provides a sorting mechanism,
and co-localizing receptors and cofactors thus being responsible for
the fine-tuning of signal transduction [54]. Cyclodextrins and β-cy-
clodextrin are able to form inclusion complexes with cholesterol. They
are commonly used to extract or insert cholesterol from membranes
[55–58]. In addition, βCDs are also known to form inclusion com-
plexes with several hydrophobic drugs [17,18,59,60] including budes-
onide (BUD).
Interestingly, clinical studies [14] showed a lower cellular toxi-
city of budesonide when budesonide was complexed with HPβCD.
The aim of the present study was therefore to understand the po-
tential effect of the extraction of cholesterol in lipid-raft domains
in relation with regulation of the inflammatory response induced by
the BUD:HPβCD complex. Thus, we characterized the interaction of
BUD:HPβCD and HPβCD with lipid model membranes containing
and lacking cholesterol and determined changes in biophysical mem-
brane properties.
In model membranes containing cholesterol, we demonstrated an
effect of BUD:HPβCD with cholesterol-enriched membranes leading
to changes in membrane biophysical properties in agreement with cho-
lesterol extraction, such as increased membrane fluidity and perme-
ability, changes in lipid packing and lipid desorption from the lipid in-
terface as well as the disruption of cholesterol-enriched raft-like liquid
ordered domains. In comparison with HPβCD and except for mem-
brane fluidity, all these effects were enhanced and/or observed earlier
with the complex BUD:HPβCD.
The molecular mechanisms involved in cholesterol extraction by
HPβCD and BUD:HPβCD was unknown but as demonstrated by
Lopez et al. [50], the distribution of the cyclodextrins on the surface
of the monolayer could play a critical role. Spontaneous cholesterol
extraction on a nanosecond time scale might be related with a suit-
ably oriented dimer. Moreover, free energy calculations reveal that the
cyclodextrins have a strong affinity to bind to the membrane surface,
and, by doing so, destabilize the local packing of cholesterol mole-
cules making their extraction favorable [50].
For the model systems lacking cholesterol, the BUD:HPβCD and
HPβCD caused an increase in DPH anisotropy for the lowest con-
centrations and the disappearance of liquid disordered/solid ordered
phase separation in GUVs. The increase of membrane rigidity is sur-
prising but can reasonably be ascribed to the formation of a rela-
tively thick polymer layer around the phospholipid bilayers [48]. In
the same line, Lopez et al. [50], reported from simulations studies,
the formation of supra-molecular cyclodextrin structures on the sur-
face of cholesterol monolayers. The mechanism of interaction of cy-
clodextrins with the lipid membrane is suggested to depend on the
molecular ratio of cyclodextrins to lipid. Since cyclodextrins possess
a greater affinity towards cholesterol when compared to phospho-
lipids, it is possible that the observed increase in membrane rigid-
ity observed for the lowest HPβCD:lipid ratio might reflect non-spe-
cific stabilizing cyclodextrin interaction with the surface of the choles-
terol-free membrane. For higher HPβCD concentrations the increase
in membrane fluidity coming back to values similar to those ob-
tained for controls might be explained by extraction of lipids other
than cholesterol, namely sphingomyelin. Moreover, at higher HPβCD
concentrations, HPβCD:HPβCD interactions could be promoted in
comparison with HPβCD:membrane interactions explaining why no
global effect was observed on membrane fluidity. Regarding the ef-
fect on membrane phase separation, in absence of cholesterol,
BUD:HPβCD affected membrane phase separation without increasing
membrane permeability and affecting (or only slightly) the stability of
SM, POPC or PI monolayers.
A critical question is the potential competition between budesonide
and lipid for the HPβCD cavity which may occur at the interface.
Focusing on the mechanism involved, the BUD:HPBCD complex in-
duced a greater destabilization of the cholesterol monolayer with-
out affecting HPBCD cholesterol extraction potential (Fig. 7a + in-
set). It resulted in an increase in surface pressure over time in mono-
layers composed of phospholipids. These results suggest an insertion
of budesonide into the air:liquid interface, an exchange between the
budesonide and cholesterol in favor of cholesterol. This could be re-
lated to the increased kinetics of membrane permeabilization to cal-
cein induced by the BUD:HPβCD complex when compared with the
HPβCD.
Altogether, the results showed that BUD:HPβCD and HPβCD can
effectively induce significant changes in the composition and biophys-
ical properties of cholesterol-enriched raft-like domains in model sys-
tems. Destabilization of these domains might explain the anti-inflam-
matory effect observed for the HPβCD (preliminary data), probably
by modifying the lipid environment of receptors involved in inflam-
matory processes. The co-administration of budesonide and HPβCD
might provide a higher therapeutic effect acting through complemen-
tary anti-inflammatory mechanisms. Thus HPβCD could play a criti-
cal role for administration of poorly soluble drug like budesonide by
increasing cellular delivery of budesonide in vivo as well as for reg-
ulation of critical biophysical membrane properties of cholesterol-en-
riched domains where immune receptors are located. HPβCD can be
both a targeted delivery vehicle and an anti-inflammatory agent by
own.
Further studies about the modulation of the inflammatory response,
focusing particularly on the relevance of lipid rafts in signal activation,
are required to evaluate the mechanism involved in BUD:HPβCD and
HPβCD anti-inflammatory properties.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2017.06.010.
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